Why Crinetics Pharmaceuticals Inc (CRNX) Stock Could Change the Game for Investors—Or Not
TD Cowen has recently initiated Crinetics Pharmaceuticals Inc (CRNX) stock to Buy rating, as announced on February 11, 2025, according to Finviz. Earlier, on February 4, 2025, Wolfe Research had initiated the stock to Peer Perform. Jefferies also raised Buy rating with a price target of $55. Additionally, Citigroup initiated Buy rating on March 6, […]
Jefferies Just Upgraded Crinetics Pharmaceuticals Inc (CRNX) Stock—What Does This Mean for Investors?
Jefferies has recently raised Crinetics Pharmaceuticals Inc (CRNX) stock to Buy rating, as announced on January 22, 2025, according to Finviz. Earlier, on March 6, 2024, Citigroup had initiated the stock to Buy, setting a price target of $68. Morgan Stanley also initiated Overweight rating with a price target of $50. Additionally, Jefferies initiated Hold […]
How Does Crinetics Pharmaceuticals Inc (CRNX) Stack Up Against Its Industry Peers?
Citigroup has recently initiated Crinetics Pharmaceuticals Inc (CRNX) stock to Buy rating, as announced on March 6, 2024, according to Finviz. Earlier, on January 16, 2024, Morgan Stanley had initiated the stock to Overweight, setting a price target of $50. Jefferies also initiated Hold rating with a price target of $35. Additionally, JP Morgan resumed […]
Crinetics Pharmaceuticals Inc (CRNX) Stock Posted a Gross Margin of -105.50% Over the Past Year: Is This Justifiable?
Citigroup has recently initiated Crinetics Pharmaceuticals Inc (CRNX) stock to Buy rating, as announced on March 6, 2024, according to Finviz. Earlier, on January 16, 2024, Morgan Stanley had initiated the stock to Overweight, setting a price target of $50. Jefferies also initiated Hold rating with a price target of $35. Additionally, JP Morgan resumed […]
Crinetics Pharmaceuticals Inc (CRNX) Stock: Unveiling Its Hidden Strengths
Citigroup has recently initiated Crinetics Pharmaceuticals Inc (CRNX) stock to Buy rating, as announced on March 6, 2024, according to Finviz. Earlier, on January 16, 2024, Morgan Stanley had initiated the stock to Overweight, setting a price target of $50. Jefferies also initiated Hold rating with a price target of $35. Additionally, JP Morgan resumed […]
The CRNX Conundrum: Why Crinetics Pharmaceuticals Inc’s Stock Is Making Headlines Again
Citigroup has recently initiated Crinetics Pharmaceuticals Inc (CRNX) stock to Buy rating, as announced on March 6, 2024, according to Finviz. Earlier, on January 16, 2024, Morgan Stanley had initiated the stock to Overweight, setting a price target of $50. Jefferies also initiated Hold rating with a price target of $35. Additionally, JP Morgan resumed […]
Why Did Crinetics Pharmaceuticals Inc (CRNX) Stock Plunge -6.15% Last Week?
Citigroup has recently initiated Crinetics Pharmaceuticals Inc (CRNX) stock to Buy rating, as announced on March 6, 2024, according to Finviz. Earlier, on January 16, 2024, Morgan Stanley had initiated the stock to Overweight, setting a price target of $50. Jefferies also initiated Hold rating with a price target of $35. Additionally, JP Morgan resumed […]
Crinetics Pharmaceuticals Inc (CRNX) Stock: More Robust Than the Numbers Suggest?
Citigroup has recently initiated Crinetics Pharmaceuticals Inc (CRNX) stock to Buy rating, as announced on March 6, 2024, according to Finviz. Earlier, on January 16, 2024, Morgan Stanley had initiated the stock to Overweight, setting a price target of $50. Jefferies also initiated Hold rating with a price target of $35. Additionally, JP Morgan resumed […]
Analysts Predict a $68 Target for Crinetics Pharmaceuticals Inc (CRNX) Stock—What Could Drive It There?
Citigroup has recently initiated Crinetics Pharmaceuticals Inc (CRNX) stock to Buy rating, as announced on March 6, 2024, according to Finviz. Earlier, on January 16, 2024, Morgan Stanley had initiated the stock to Overweight, setting a price target of $50. Jefferies also initiated Hold rating with a price target of $35. Additionally, JP Morgan resumed […]
CRNX’s Latest Twist: What’s Fueling the Unexpected Shifts in Crinetics Pharmaceuticals Inc’s Stock Price?
Citigroup has recently initiated Crinetics Pharmaceuticals Inc (CRNX) stock to Buy rating, as announced on March 6, 2024, according to Finviz. Earlier, on January 16, 2024, Morgan Stanley had initiated the stock to Overweight, setting a price target of $50. Jefferies also initiated Hold rating with a price target of $35. Additionally, JP Morgan resumed […]
